Hemann Lab Selected Publications

Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. (2011). Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Res., 71(17), 5850-5858. PMCID: PMC3165087

Gilbert LA, Hemann MT. (2011). Chemotherapeutic resistance: surviving stressful situations. Cancer Res., 71(15), 5062-5066. PMCID: PMC3148403

Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol., 7(2), 92-100. PMCID: PMC3070540

Xie K, Doles J, Hemann MT, Walker GC. (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc. Natl. Acad. Sci. USA, 107(48), 20792-20797. PMCID: PMC2996453

Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. (2010) Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc. Natl. Acad. Sci. USA, 107(48), 20786-20791. PMCID: PMC2996428

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. (2010). Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature., 468(7323), 572-557. PMCID: PMC3003305

Gilbert LA, Hemann MT. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell, 143(3), 355-366. PMCID: PMC2972353

Doles J and Hemann MT. NEK4 status affects differential sensitivity to microtubule poisons. Cancer Res. 2010 Feb 1;70(3):1033-41. PMCID: PMC2946156

Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. Oct 6;16(4):324-35. PMCID: PMC2829755

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. (2009). Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle., 8(19), 3112-3119. PMCID: PMC3057180

Meacham CE, Ho E, Dubrovsky E, Gertler FB and Hemann MT. In Vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics, (2009) Oct;41(10): 1133-1137. PMCID: PMC2756700

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes & Development, (2009) Aug 15;23(16) 1895-1909. PMCID: PMC2725944

Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. (2009). Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther., 8(8), 2183-2192. PMCID: PMC2779718

Burgess, D.J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W.R., Hannon, G.J., Lowe, S.W., Hemann, M.T. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci, 105(26), 9053-9058. PMCID: PMC2435590.